(IN BRIEF) GSK and the University of Oxford have launched the GSK-Oxford Cancer Immuno-Prevention Programme, a new research initiative focused on cancer prevention through vaccination. GSK is investing up to £50 million to explore how precancerous cells develop into cancer, … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Cancer Prevention, cancer vaccines, clinical trials, early-stage cancer, GSK, GSK-Oxford Cancer Immuno-Prevention Programme, GSK’s immune system expertise, immune system, immuno-oncology, Institute of Molecular and Computational Medicine, neoantigen sequencing, neoantigens, Peter Kyle, precancer biology, Professor Irene Tracey, targeted therapies, Tony Wood, translational research, tumor-specific proteins, University of Oxford, vaccination, vaccinology
(IN BRIEF) Researchers at the University of Twente, led by Prof. Massimo Sartori, in collaboration with McGill University and Griffith University, have developed CEINMS-RT, an open-source platform designed to advance wearable robotics. This platform enables real-time, neuro-mechanical model-based control for … Read the full press release
Posted in Education, Industrial, Science, Technology
Tagged athletic performance, back-support exosuits, biofeedback, biomechanical modeling, bionic limbs, CEINMS-RT, clinical trials, electromyography, ET, exoskelet, exoskeletons, exosuits, GitHub repository, Griffith University, human movement augmentation, human-machine interfaces, joint dynamics, joint stiffness estimation, McGill University, mobility impairments, muscle activation, muscle fatigue modeling, neuro-mechanical model-based control, onexosuit, open-source, open-source platform, personalized control strategies, Prof. Massimo Sartori, real-time contol, real-time control, recovery, rehabilitation, robotics, task-agnostic control, tendon forces, University of Twente, wearable devices, wearable robotics
(IN BRIEF) Sanofi’s Sarclisa has been approved by the European Union as the first anti-CD38 therapy in combination with VRd to treat adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. This approval is … Read the full press release
Posted in Business, European Union, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged CD38 monoclonal antibody, clinical development, clinical trials, European Union approval, FDA approval, hematologic malignancies, immunoscience, isatuximab, Multiple Myeloma, NDMM, oncology, orphan drug exclusivity, Sanofi, Sarclisa, transplant-ineligible, treatment breakthrough, VRd
(IN BRIEF) Evonik has partnered with ST Pharm to enhance its RNA and nucleic acid therapeutic services, combining ST Pharm’s expertise in customized nucleic acids with Evonik’s advanced lipid and lipid nanoparticle (LNP) drug product development solutions. This collaboration aims … Read the full press release
Posted in Business, Chemicals, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged active ingredients, capping library screening, clinical trials, drug delivery, drug development, drug product development, enzymatic biotransformation, Evonik, Evonik capabilities, Fill & Finish, gene delivery, gene therapies, GMP manufacturing, Health Care Business, Kris S. Choi, life sciences sector, lipid nanoparticle, lipids, liposomes, LNP, mRNA development, mRNA-LNPs, North America manufacturing, nucleic acid medicines, nucleic acid therapeutics, nucleic acid therapies, Nutrition & Care division, oligonucleotides, partnership, pharmaceutical companies, RNA market, RNA therapeutics, siRNAs, small molecules, SmartCap® technology, South Korea, ST Pharm, strategic partnership, Yann d'Hervé
(IN BRIEF) The Conference Forum announced the launch of the 8th annual Patients as Partners® Europe meeting, scheduled for May 14-15, 2024, at Plaisterers’ Hall in London, England. This event brings together pharma R&D and patient advocacy to discuss patient … Read the full press release
Posted in Healthcare, Marketing, Pharma & Biotech, United Kingdom
Tagged 8th annual Patients as Partners® Europe, AbbVie, Anders Lassen, Andrew Garvey, Annie Gilbert, Astellas, AstraZeneca, Biotech, Boehringer Ingelheim, clinical operations, clinical research, clinical trials, Conference, David James, decentralized clinical trials, Derek Stewart, diversifying clinical trials, diversity, drug development, England, GSK, Health Equity, inclusivity, inclusivity in clinical research, Ipsen, LGBTQ+ oncology, Lisa Kerr, London, Lundbeck, Novartis, Novo Nordisk, Oleksandr Gorbenko, Parexel, Patient Advocacy, patient engagment, patient experience mapping, Patrick Gallogly, Pfizer, pharma, Plaisterers’ Hall, Prostate Cancer Research, Rosamund Round, Sanofi, Sarah Zenner Dolan, Stephen Head, The Conference Forum, Valerie Bowling, Victoria DiBiaso, , Alfred Samuel
(IN BRIEF) Novadip, a Belgian biotech company, has secured €18 million in venture debt financing from the European Investment Bank (EIB) with support from the European Union’s InvestEU initiative. The funds will be utilized for clinical trials of NVD-003, an … Read the full press release
(IN BRIEF) Medidata, a subsidiary of Dassault Systèmes, has introduced the Medidata Diversity Program, an extensive solution aimed at enhancing diversity, equity, and inclusion in clinical trials. This program supports biopharmaceutical companies, medical device firms, and clinical research organizations (CROs) … Read the full press release
(IN BRIEF) The Conference Forum has announced that the 7th annual European Patients as Partners® in Clinical Research conference will take place in London on June 12-13, 2023. The event will focus on achieving greater representation in clinical research, building … Read the full press release
Posted in Government, Healthcare, News, Non Profit, Pharma & Biotech, United Kingdom
Tagged 7th annual European Patients as Partners®, biotechnology, Boehringer Ingelheim, Center for BME Health, clinical development, clinical research, Clinical Research conference, clinical trials, Community Engagement, CSL Behring, Deirdre BeVard, Diversity in Clinical Research, drug development, government, Health Equity, Healthcare, Hospital, Lundbeck, Medicine Development, Medicine Lifestyle, Medicines Development, Novartis, Patient Advocacy, Patient Centricity, Patient Communities, patient engagement, Patient Perspective, Patient Recruitment, Patient Retention, Patient Voice, Patients as Partners, Pharmaceutical, research and development, Sanofi, The Conference Forum, Thistle Hotel Marble Arch, Valerie Bowling
(PRESS RELEASE) New York, NY, United States, 5-Jan-2022 — /EuropaWire/ — The Conference Forum announced the launch of the 6th annual EU Patients as Partners in Medicines Development conference to take place virtually on January 24-25th, 2022 GMT time. This … Read the full press release
Posted in Education, Healthcare, Internet & Online, News, Pharma & Biotech, Science, Technology
Tagged 6th annual EU Patients as Partners, AbbVie, Biotech, clinical development, clinical research, clinical trial, clinical trials, Conference, Conference Forum, data, dct, decentralized, DNA, EMD Serono, Gilead Sciences, GSK, INNOVATION, Ipsen, Janssen, Johnson & Johnson, Medicines Development, Merck KGaA, Michaela Dinboeck, MS trial, Noema Pharma, Novartis, Parkinsons disease, patient engagement, patient input, Patient Voice, patients, Patients as Partners Europe, Pfizer, pharma, Pharmaceutical, Pierre Fabre, Regeneron, Takeda, UCB
Increased efficacy with longer inter-dose interval Protection of over 70% starting after a first dose First indication of reduction in disease transmission of up to 67% (PRESS RELEASE) CAMBRIDGE, 3-Feb-2021 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British–Swedish multinational pharmaceutical … Read the full press release
In a post-hoc analysis of HAWK and HARRIER, fewer Beovu (brolucizumab) patients had early persistent fluid (12.5% vs. 20.4% of aflibercept patients), defined as the presence of intra-retinal fluid and/or sub-retinal fluid through week 12 of treatment1 Patients with early persistent fluid treated with Beovu experienced greater … Read the full press release
Paris, France, 21-11-2013 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the decision to halt all clinical trials and cancel plans for regulatory filings with its investigational JAK2 inhibitor, fedratinib (SAR302503). Following a thorough risk-benefit analysis, including consultation with the U.S. … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?